Testing a new drug combined with radiation for brain tumors
Official title: Development of the brain penetrant ATM inhibitor WSD0628 in combination with radiation for recurrent high grade glioma
Funded at Mayo Clinic Rochester · NIH-10929435 · Data updated 2026-11-12
This study is looking at a new drug called WSD0628 to see if it can help make radiation therapy work better for patients with recurrent high-grade gliomas, like glioblastoma, while keeping side effects low.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 10, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $649,264 |
| NIH project number | 5R01FD007842-02 |
| Project ID | NIH-10929435 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with recurrent high-grade gliomas who have undergone prior treatments.
✕Less likely to help
Patients with low-grade gliomas or those who have not been diagnosed with gliomas may not benefit from this research.
What this research studies
This research investigates the use of a new drug, WSD0628, that can penetrate the brain and enhance the effectiveness of radiation therapy for patients with recurrent high-grade gliomas, such as glioblastoma. The study aims to evaluate the safety and efficacy of this drug in combination with radiation, building on promising pre-clinical results that suggest it can improve tumor control without increasing harmful side effects in the central nervous system. Patients will be monitored for their response to treatment and any potential side effects.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with high-grade gliomas, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results with similar approaches, indicating potential for success in this novel application.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Sarkaria, Jann N. — Mayo Clinic Rochester
- Study coordinator: Sarkaria, Jann N.
Related research
Other NIH-funded projects on the same topics.
-
Liquid biopsy for monitoring high-grade glioma using patient-specific DNA junctions
A Mayo Clinic team tests a blood test that looks for unique tumor DNA pieces in glioblastoma patients to monitor disease without frequent scans.
-
Canine and human high-grade gliomas: linking dog and human tumor biology to guide better treatments
A study in dogs with high-grade glioma aims to reveal parallels to human brain tumors so that treatments looked promising in dogs might translate to people.
-
Targeted study on a pediatric brain cancer subtype with specific gene mutations
A study to understand why a rare form of high-grade brain cancer in young people develops and to find new treatment targets.
-
PEP-CMV vaccine with nivolumab for pediatric and adult high-grade brain tumors
A phase 1/2 trial tests a CMV-targeted vaccine plus a PD-1 blocker for newly diagnosed and recurrent high-grade brain tumors in children and adults.
-
Better MRI detection and classification of invasive high-grade brain tumors
This project uses advanced MRI scans to spot and tell apart invasive types of high-grade brain tumors so doctors can find tumor cells that hide beyond standard scans.
-
Finding weaknesses in G34‑mutant high‑grade brain tumors
This project looks at how specific genetic changes in G34‑mutant high‑grade brain tumors that affect adolescents and young adults create weaknesses that could point to new treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.